PMID- 21914348
OWN - NLM
STAT- MEDLINE
DCOM- 20120227
LR  - 20160818
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 40
IP  - 6
DP  - 2011 Jun
TI  - [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle 
      aspiration specimens].
PG  - 392-6
AB  - OBJECTIVE: To investigate diagnostic values of the detection of TMPRSS2-ERG gene 
      fusion in metastatic prostate cancer. METHODS: A total of 32 fine needle 
      aspiration (FNA) specimens of metastatic prostate carcinomas were retrieved from 
      the pathology files at MD Anderson Cancer Center. The metastatic sites included 
      the pelvic and remote lymph nodes, liver, bone, and thyroid gland. 
      Immunohistochemical staining for PSA, PAP, synaptophysin, chromogranin A was 
      performed. TMPRSS2-ERG gene fusion was evaluated on sections of cell blocks by 
      fluorescence in situ hybridization (FISH) using ERG gene break-apart probes. 
      RESULTS: The mean age of the patients was 67 years. Twenty-six patients had a 
      previous history of prostatic adenocarcinoma, while 6 patients presented 
      initially with metastasis. In 11 patients, the metastatic lesions showed 
      characteristic features of small cell carcinoma (SCC) and were positive for 
      synaptophysin (9/9), chromogranin A (7/8), but negative for prostatic specific 
      antigen (7/7). FISH analysis demonstrated a rearrangement of ERG gene in 10 of 32 
      cases (31.3%), and the rearrangement was associated with deletion of the 5' ERG 
      gene in 6 cases. In addition, the copy number of ERG rearrangement gene locus was 
      increased in 8 cases. Among the 11 cases with SCC features, a rearrangement of 
      ERG gene was present in 5 cases, of which a deletion of the 5' ERG gene and 
      increased copy number were seen in 3 cases. CONCLUSIONS: TMPRSS2-ERG gene fusion 
      can be evaluated in FNA specimens of metastatic prostate cancer. Metastatic 
      prostate cancers have a high prevalence of TMPRSS2-ERG gene fusion along with a 
      frequent copy number increase of ERG gene. TMPRSS2-ERG gene fusion persists in 
      metastatic prostate cancers and even in those with poorly differentiated SCC 
      features. Therefore, an identification of the TMPRSS2-ERG gene fusion may be used 
      to establish the prostatic origin of metastasis.
FAU - Xiao, Li
AU  - Xiao L
AD  - Department of Pathology, Huadong Hospital, Fudan University, Shanghai 200040, 
      China.
FAU - Zhu, Xiong-zeng
AU  - Zhu XZ
FAU - Wang, Yan
AU  - Wang Y
FAU - Gong, Yun
AU  - Gong Y
FAU - Guo, C Charles
AU  - Guo CC
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Chromogranin A)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Synaptophysin)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - EC 3.1.3.2 (prostatic acid phosphatase)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Acid Phosphatase
MH  - Adenocarcinoma/*genetics/metabolism/pathology/secondary/surgery
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Fine-Needle
MH  - Carcinoma, Small Cell/genetics/metabolism/pathology/secondary/surgery
MH  - Chromogranin A/metabolism
MH  - Follow-Up Studies
MH  - *Gene Fusion
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Liver Neoplasms/genetics/metabolism/pathology/*secondary/surgery
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics/metabolism
MH  - Prostate-Specific Antigen/metabolism
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology/surgery
MH  - Protein Tyrosine Phosphatases/metabolism
MH  - Synaptophysin/metabolism
EDAT- 2011/09/15 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/09/15 06:00
PHST- 2011/09/15 06:00 [entrez]
PHST- 2011/09/15 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6.